Boston Scientific Cleared For Next-Gen Deep Vein Thrombosis Catheter
This article was originally published in The Gray Sheet
Executive Summary
A year after Boston Sci bought Bayer's interventional unit, Medrad, the company says it has received a 510(k) clearance for its ZelanteDVT catheter to be used with its AngioJet Ultra Console to treat deep vein thrombosis as mechanical – rather than drug – DVT treatments are gaining more attention.
You may also be interested in...
Not Too ATTRACTive Data For Catheter Thrombolysis In Combatting Post-Thrombotic Syndrome
Randomized trial results show pharmacomechanical, catheter-directed thrombolysis does not reduce the development of post-thrombotic syndrome in patients treated for deep-vein thrombosis. The study’s investigator suggests limiting the procedure to treatment of large iliofemoral blood clots causing major symptoms in patients who are at low risk of bleeding.
Pierre Fabre Continues Oncology R&D Push
The French firm has followed up its recent acquisition of Swiss lung cancer specialist Vertical Bio by signing a pact with Vernalis.
Novartis’s Lutathera To Be First Radiopharmaceutical In Frontline Use After Trial Success
The Swiss pharma giant is building momentum in radiopharmaceuticals by racking up positive pivotal trial data and overcoming manufacturing bottlenecks.